Sagimet Biosciences
SGMT
70 hedge funds and large institutions have $44.9M invested in Sagimet Biosciences in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 13 closing their positions.
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
24% more call options, than puts
Call options by funds: $539K | Put options by funds: $436K
6% more funds holding
Funds holding: 66 → 70 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
12.14% less ownership
Funds ownership: 57.04% → 44.9% (-12%)
43% less capital invested
Capital invested by funds: $78.8M → $44.9M (-$33.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.45M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.02M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$609K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$213K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.94M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.35M |
| 4 |
Millennium Management
New York
|
-$2.23M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$761K |
SGMT Hedge Fund Activity: Q1 2025 in Review
70 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q1 2025, worth a combined $44.9M — down 43% from $78.8M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SGMT positions and 13 closed out — a net gain of 5 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was Raymond James Financial, opening a new position worth an estimated $1.45M. The largest seller was NEA Management Company, exiting entirely with an estimated $9M sold.
- 70 institutional investors held Sagimet Biosciences (SGMT) as of Q1 2025, up from 66 in Q4 2024.
- Funds reported $44.9M of Sagimet Biosciences stock for Q1 2025, down 43% quarter-over-quarter.
- 18 funds opened new Sagimet Biosciences positions in Q1 2025 and 13 closed out, a net change of +5 holders.
- The largest Sagimet Biosciences buyer in Q1 2025 was Raymond James Financial, an estimated $1.45M added.
- The largest Sagimet Biosciences seller in Q1 2025 was NEA Management Company, an estimated $9M sold.
Based on aggregated 13F filings for Q1 2025.